nach oben

Cancer and Metastasis Reviews

Erschienen in:

01.06.2008

PRL PTPs: mediators and markers of cancer progression

verfasst von: Darrell C. Bessette, Dexin Qiu, Catherine J. Pallen

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 2/2008

Einloggen, um Zugang zu erhalten

Abstract

Aberrant protein tyrosine phosphorylation resulting from the altered activity of protein tyrosine phosphatases (PTPs) is increasingly being implicated in the genesis and progression of human cancer. Accumulating evidence indicates that the dysregulated expression of members of the phosphatase of regenerating liver (PRL) subgroup of PTPs is linked to these processes. Enhanced expression of the PRLs, notably PRL-1 and PRL-3, promotes the acquisition of cellular properties that confer tumorigenic and metastatic abilities. Up-regulation of PRL-3 is associated with the progression and eventual metastasis of several types of human cancer. Indeed, PRL-3 shows promise as a biomarker and prognostic indicator in colorectal, breast, and gastric cancers. However, the substrates and molecular mechanisms of action of the PRLs have remained elusive. Recent findings indicate that PRLs may function in regulating cell adhesion structures to effect epithelial-mesenchymal transition. The identification of PRL substrates is key to understanding their roles in cancer progression and exploiting their potential as exciting new therapeutic targets for cancer treatment.

Mohn, K. L., Laz, T. M., Hsu, J. C., Melby, A. E., Bravo, R., & Taub, R. (1991). The immediate-early growth response in regenerating liver and insulin-stimulated H-35 cells: comparison with serum-stimulated 3T3 cells and identification of 41 novel immediate-early genes. Molecular and Cellular Biology, 11, 381–390.PubMed

Diamond, R. H., Cressman, D. E., Laz, T. M., Abrams, C. S., & Taub, R. (1994). PRL-1, a unique nuclear protein tyrosine phosphatase, affects cell growth. Molecular and Cellular Biology, 14, 3752–3762.PubMed

Montagna, M., Serova, O., Sylla, B. S., Feunteun, J., & Lenoir, G. M. (1995). A 100-kb physical and transcriptional map around the EDH17B2 gene: identification of three novel genes and a pseudogene of a human homologue of the rat PRL-1 tyrosine phosphatase. Human Genetics, 96, 532–538.PubMedCrossRef

Cates, C. A., Michael, R. L., Stayrook, K. R., Harvey, K. A., Burke, Y. D., Randall, S. K., et al. (1996). Prenylation of oncogenic human PTP(CAAX) protein tyrosine phosphatases. Cancer Letters, 110, 49–55.PubMedCrossRef

Zeng, Q., Hong, W., & Tan, Y. H. (1998). Mouse PRL-2 and PRL-3, two potentially prenylated protein tyrosine phosphatases homologous to PRL-1. Biochemical and Biophysical Research Communications, 244, 421–427.PubMedCrossRef

Zeng, Q., Si, X., Horstmann, H., Xu, Y., Hong, W., & Pallen, C. J. (2000). Prenylation-dependent association of protein-tyrosine phosphatases PRL-1, -2, and -3 with the plasma membrane and the early endosome. Journal of Biological Chemistry, 275, 21444–21452.PubMedCrossRef

Sun, J. P., Wang, W. Q., Yang, H., Liu, S., Liang, F., Fedorov, A. A., et al. (2005). Structure and biochemical properties of PRL-1, a phosphatase implicated in cell growth, differentiation, and tumor invasion. Biochemistry, 44, 12009–12021.PubMedCrossRef

Jeong, D. G., Kim, S. J., Kim, J. H., Son, J. H., Park, M. R., Lim, S. M., et al. (2005). Trimeric structure of PRL-1 phosphatase reveals an active enzyme conformation and regulation mechanisms. Journal of Molecular Biology, 345, 401–413.PubMedCrossRef

Kim, K. A., Song, J. S., Jee, J., Sheen, M. R., Lee, C., Lee, T. G., et al. (2004). Structure of human PRL-3, the phosphatase associated with cancer metastasis. FEBS Letters, 565, 181–187.PubMedCrossRef

10.

Kozlov, G., Cheng, J., Ziomek, E., Banville, D., Gehring, K., & Ekiel, I. (2004). Structural insights into molecular function of the metastasis-associated phosphatase PRL-3. Journal of Biological Chemistry, 279, 11882–11889.PubMedCrossRef

11.

Zhou, H., Gallina, M., Mao, H., Nietlispach, D., Betz, S. F., Fetrow, J. S., et al. (2003). 1H, 13C and 15N resonance assignments and secondary structure of the human protein tyrosine phosphatase, PRL-2. Journal of Biomolecular NMR, 27, 397–398.PubMedCrossRef

12.

Barford, D., Das, A. K., & Egloff, M. P. (1998). The structure and mechanism of protein phosphatases: Insights into catalysis and regulation. Annual Review of Biophysics and Biomolecular Structure, 27, 133–164.PubMedCrossRef

13.

Denu, J. M., Stuckey, J. A., Saper, M. A., & Dixon, J. E. (1996). Form and function in protein dephosphorylation. Cell, 87, 361–364.PubMedCrossRef

14.

Zhang, Z. Y. (1998). Protein-tyrosine phosphatases: Biological function, structural characteristics, and mechanism of catalysis. Critical Reviews in Biochemistry and Molecular Biology, 33, 1–52.PubMedCrossRef

15.

Wang, J., Kirby, C. E., & Herbst, R. (2002). The tyrosine phosphatase PRL-1 localizes to the endoplasmic reticulum and the mitotic spindle and is required for normal mitosis. Journal of Biological Chemistry, 277, 46659–46668.PubMedCrossRef

16.

Zhang, Z. Y., Palfey, B. A., Wu, L., & Zhao, Y. (1995). Catalytic function of the conserved hydroxyl group in the protein tyrosine phosphatase signature motif. Biochemistry, 34, 16389–16396.PubMedCrossRef

17.

Denu, J. M., & Dixon, J. E. (1995). A catalytic mechanism for the dual-specific phosphatases. Proceedings of the National Academy of Sciences of the United States of America, 92, 5910–5914.PubMedCrossRef

18.

Sun, J. P., Luo, Y., Yu, X., Wang, W. Q., Zhou, B., Liang, F., et al. (2007). Phosphatase activity, trimerization, and the C-terminal polybasic region are all required for PRL1-mediated cell growth and migration. Journal of Biological Chemistry, 282, 29043–29051.PubMedCrossRef

19.

Yu, L., Kelly, U., Ebright, J. N., Malek, G., Saloupis, P., Rickman, D. W., et al. (2007). Oxidative stress-induced expression and modulation of Phosphatase of Regenerating Liver-1 (PRL-1) in mammalian retina. Biochimica et Biophysica Acta, 1773, 1473–1482.PubMed

20.

Dumaual, C. M., Sandusky, G. E., Crowell, P. L., & Randall, S. K. (2006). Cellular localization of PRL-1 and PRL-2 gene expression in normal adult human tissues. Journal of Histochemistry and Cytochemistry, 54, 1401–1412.PubMedCrossRef

21.

Matter, W. F., Estridge, T., Zhang, C., Belagaje, R., Stancato, L., Dixon, J., et al. (2001). Role of PRL-3, a human muscle-specific tyrosine phosphatase, in angiotensin-II signaling. Biochemical and Biophysical Research Communications, 283, 1061–1068.PubMedCrossRef

22.

Wang, Q., Holmes, D. I., Powell, S. M., Lu, Q. L., & Waxman, J. (2002). Analysis of stromal–epithelial interactions in prostate cancer identifies PTPCAAX2 as a potential oncogene. Cancer Letters, 175, 63–69.PubMedCrossRef

23.

Kato, H., Semba, S., Miskad, U. A., Seo, Y., Kasuga, M., & Yokozaki, H. (2004). High expression of PRL-3 promotes cancer cell motility and liver metastasis in human colorectal cancer: A predictive molecular marker of metachronous liver and lung metastases. Clinical Cancer Research, 10, 7318–7328.PubMedCrossRef

24.

Miskad, U. A., Semba, S., Kato, H., & Yokozaki, H. (2004). Expression of PRL-3 phosphatase in human gastric carcinomas: close correlation with invasion and metastasis. Pathobiology, 71, 176–184.PubMedCrossRef

25.

Rouleau, C., Roy, A., St Martin, T., Dufault, M. R., Boutin, P., Liu, D., et al. (2006). Protein tyrosine phosphatase PRL-3 in malignant cells and endothelial cells: expression and function. Molecular Cancer Therapeutics, 5, 219–229.PubMedCrossRef

26.

Radke, I., Gotte, M., Kersting, C., Mattsson, B., Kiesel, L., & Wulfing, P. (2006). Expression and prognostic impact of the protein tyrosine phosphatases PRL-1, PRL-2, and PRL-3 in breast cancer. British Journal of Cancer, 95, 347–354.PubMedCrossRef

27.

Si, X., Zeng, Q., Ng, C. H., Hong, W., & Pallen, C. J. (2001). Interaction of farnesylated PRL-2, a protein-tyrosine phosphatase, with the beta-subunit of geranylgeranyltransferase II. Journal of Biological Chemistry, 276, 32875–32882.PubMedCrossRef

28.

Fiordalisi, J. J., Keller, P. J., & Cox, A. D. (2006). PRL tyrosine phosphatases regulate rho family GTPases to promote invasion and motility. Cancer Research, 66, 3153–3161.PubMedCrossRef

29.

Diamond, R. H., Peters, C., Jung, S. P., Greenbaum, L. E., Haber, B. A., Silberg, D. G., et al. (1996). Expression of PRL-1 nuclear PTPase is associated with proliferation in liver but with differentiation in intestine. American Journal of Physiology, 271, G121–129.PubMed

30.

Kong, W., Swain, G. P., Li, S., & Diamond, R. H. (2000). PRL-1 PTPase expression is developmentally regulated with tissue-specific patterns in epithelial tissues. American Journal of Physiology -l Gastrointestinal and Liver Physiology, 279, G613–G621.

31.

Yarovinsky, T. O., Rickman, D. W., Diamond, R. H., Taub, R., Hageman, G. S., & Bowes Rickman, C. (2000). Expression of the protein tyrosine phosphatase, phosphatase of regenerating liver 1, in the outer segments of primate cone photoreceptors. Brain Research. Molecular Brain Research, 77, 95–103.PubMedCrossRef

32.

Saha, S., Bardelli, A., Buckhaults, P., Velculescu, V. E., Rago, C., St Croix, B., et al. (2001). A phosphatase associated with metastasis of colorectal cancer. Science, 294, 1343–1346.PubMedCrossRef

33.

Bardelli, A., Saha, S., Sager, J. A., Romans, K. E., Xin, B., Markowitz, S. D., et al. (2003). PRL-3 expression in metastatic cancers. Clinical Cancer Research, 9, 5607–5615.PubMed

34.

Li, J., Guo, K., Koh, V. W., Tang, J. P., Gan, B. Q., Shi, H., et al. (2005). Generation of PRL-3- and PRL-1-specific monoclonal antibodies as potential diagnostic markers for cancer metastases. Clinical Cancer Research, 11, 2195–2204.PubMedCrossRef

35.

Peng, L., Ning, J., Meng, L., & Shou, C. (2004). The association of the expression level of protein tyrosine phosphatase PRL-3 protein with liver metastasis and prognosis of patients with colorectal cancer. Journal of Cancer Research and Clinical Oncology, 130, 521–526.PubMedCrossRef

36.

Wang, Y., Li, Z. F., He, J., Li, Y. L., Zhu, G. B., & Zhang, L. H. (2007). Expression of the human phosphatases of regenerating liver (PRLs) in colonic adenocarcinoma and its correlation with lymph node metastasis. International Journal of Colorectal Disease, 22, 1179–1184.PubMedCrossRef

37.

Wang, L., Peng, L., Dong, B., Kong, L., Meng, L., Yan, L., et al. (2006). Overexpression of phosphatase of regenerating liver-3 in breast cancer: Association with a poor clinical outcome. Annals of Oncology, 17, 1517–1522.PubMedCrossRef

38.

Miskad, U. A., Semba, S., Kato, H., Matsukawa, Y., Kodama, Y., Mizuuchi, E., et al. (2007). High PRL-3 expression in human gastric cancer is a marker of metastasis and grades of malignancies: An in situ hybridization study. Virchows Archiv, 450, 303–310.PubMedCrossRef

39.

Li, Z. R., Wang, Z., Zhu, B. H., He, Y. L., Peng, J. S., Cai, S. R., et al. (2007). Association of tyrosine PRL-3 phosphatase protein expression with peritoneal metastasis of gastric carcinoma and prognosis. Surgery Today, 37, 646–651.PubMedCrossRef

40.

Wu, X., Zeng, H., Zhang, X., Zhao, Y., Sha, H., Ge, X., et al. (2004). Phosphatase of regenerating liver-3 promotes motility and metastasis of mouse melanoma cells. American Journal of Pathology, 164, 2039–2054.PubMed

41.

Polato, F., Codegoni, A., Fruscio, R., Perego, P., Mangioni, C., Saha, S., et al. (2005). PRL-3 phosphatase is implicated in ovarian cancer growth. Clinical Cancer Research, 11, 6835–6839.PubMedCrossRef

42.

Yamashita, S., Masuda, Y., Matsumoto, K., Okumura, Y., Matsuzaki, H., Kurizaki, T., et al. (2007). Down-regulation of the human PRL-3 gene is associated with the metastasis of primary non-small cell lung cancer. Annals of Thoracic and Cardiovascular Surgery, 13, 236–239.PubMed

43.

Zeng, Q., Dong, J. M., Guo, K., Li, J., Tan, H. X., Koh, V., et al. (2003). PRL-3 and PRL-1 promote cell migration, invasion, and metastasis. Cancer Research, 63, 2716–2722.PubMed

44.

Guo, K., Li, J., Tang, J. P., Koh, V., Gan, B. Q., & Zeng, Q. (2004). Catalytic domain of PRL-3 plays an essential role in tumor metastasis: Formation of PRL-3 tumors inside the blood vessels. Cancer Biology & Therapy, 3, 945–951.CrossRef

45.

Qian, F., Li, Y. P., Sheng, X., Zhang, Z. C., Song, R., Dong, W., et al. (2007). PRL-3 siRNA inhibits the metastasis of B16-BL6 mouse melanoma cells in vitro and in vivo. Molecular Medicine, 13, 151–159.PubMed

46.

Li, Z., Zhan, W., Wang, Z., Zhu, B., He, Y., Peng, J., et al. (2006). Inhibition of PRL-3 gene expression in gastric cancer cell line SGC7901 via microRNA suppressed reduces peritoneal metastasis. Biochemical and Biophysical Research Communications, 348, 229–237.PubMedCrossRef

47.

St Croix, B., Rago, C., Velculescu, V., Traverso, G., Romans, K. E., Montgomery, E., et al. (2000). Genes expressed in human tumor endothelium. Science, 289, 1197–1202.PubMedCrossRef

48.

Guo, K., Li, J., Wang, H., Osato, M., Tang, J. P., Quah, S. Y., et al. (2006). PRL-3 initiates tumor angiogenesis by recruiting endothelial cells in vitro and in vivo. Cancer Research, 66, 9625–9635.PubMedCrossRef

49.

Wang, H., Quah, S. Y., Dong, J. M., Manser, E., Tang, J. P., & Zeng, Q. (2007). PRL-3 down-regulates PTEN expression and signals through PI3K to promote epithelial-mesenchymal transition. Cancer Research, 67, 2922–2926.PubMedCrossRef

50.

Nicholson, K. M., & Anderson, N. G. (2002). The protein kinase B/Akt signalling pathway in human malignancy. Cellular Signalling, 14, 381–395.PubMedCrossRef

51.

Dillon, R. L., White, D. E., & Muller, W. J. (2007). The phosphatidyl inositol 3-kinase signaling network: Implications for human breast cancer. Oncogene, 26, 1338–1345.PubMedCrossRef

52.

Altomare, D. A., & Testa, J. R. (2005). Perturbations of the AKT signaling pathway in human cancer. Oncogene, 24, 7455–7464.PubMedCrossRef

53.

Larue, L., & Bellacosa, A. (2005). Epithelial–mesenchymal transition in development and cancer: Role of phosphatidylinositol 3′ kinase/AKT pathways. Oncogene, 24, 7443–7454.PubMedCrossRef

54.

Thiery, J. P., & Sleeman, J. P. (2006). Complex networks orchestrate epithelial–mesenchymal transitions. Nature Reviews Molecular Cell Biology, 7, 131–142.PubMedCrossRef

55.

Guarino, M., Rubino, B., & Ballabio, G. (2007). The role of epithelial–mesenchymal transition in cancer pathology. Pathology, 39, 305–318.PubMedCrossRef

56.

Barbera, M. J., Puig, I., Dominguez, D., Julien-Grille, S., Guaita-Esteruelas, S., Peiro, S., et al. (2004). Regulation of Snail transcription during epithelial to mesenchymal transition of tumor cells. Oncogene, 23, 7345–7354.PubMedCrossRef

57.

Zhou, B. P., Deng, J., Xia, W., Xu, J., Li, Y. M., Gunduz, M., et al. (2004). Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial–mesenchymal transition. Nature Cell Biology, 6, 931–940.PubMedCrossRef

58.

Julien, S., Puig, I., Caretti, E., Bonaventure, J., Nelles, L., van Roy, F., et al. (2007). Activation of NF-kappaB by Akt upregulates Snail expression and induces epithelium mesenchyme transition. Oncogene, 26, 7445–7456.PubMedCrossRef

59.

Li, Z., Wang, L., Zhang, W., Fu, Y., Zhao, H., Hu, Y., et al. (2007). Restoring E-cadherin-mediated cell–cell adhesion increases PTEN protein level and stability in human breast carcinoma cells. Biochemical and Biophysical Research Communications, 363, 165–170.PubMedCrossRef

60.

Watabe-Uchida, M., Uchida, N., Imamura, Y., Nagafuchi, A., Fujimoto, K., Uemura, T., et al. (1998). Alpha-Catenin-vinculin interaction functions to organize the apical junctional complex in epithelial cells. Journal of Cell Biology, 142, 847–857.PubMedCrossRef

61.

Kawajiri, A., Itoh, N., Fukata, M., Nakagawa, M., Yamaga, M., Iwamatsu, A., et al. (2000). Identification of a novel beta-catenin-interacting protein. Biochemical and Biophysical Research Communications, 273, 712–717.PubMedCrossRef

62.

Subauste, M. C., Nalbant, P., Adamson, E. D., & Hahn, K. M. (2005). Vinculin controls PTEN protein level by maintaining the interaction of the adherens junction protein beta-catenin with the scaffolding protein MAGI-2. Journal of Biological Chemistry, 280, 5676–5681.PubMedCrossRef

63.

Hehlgans, S., Haase, M., & Cordes, N. (2007). Signalling via integrins: Implications for cell survival and anticancer strategies. Biochimica et Biophysica Acta, 1775, 163–180.PubMed

64.

Mitra, S. K., & Schlaepfer, D. D. (2006). Integrin-regulated FAK-Src signaling in normal and cancer cells. Current Opinion in Cell Biology, 18, 516–523.PubMedCrossRef

65.

Peng, L., Jin, G., Wang, L., Guo, J., Meng, L., & Shou, C. (2006). Identification of integrin alpha1 as an interacting protein of protein tyrosine phosphatase PRL-3. Biochemical and Biophysical Research Communications, 342, 179–183.PubMedCrossRef

66.

Liang, F., Liang, J., Wang, W. Q., Sun, J. P., Udho, E., & Zhang, Z. Y. (2007). PRL3 promotes cell invasion and proliferation by down-regulation of Csk leading to Src activation. Journal of Biological Chemistry, 282, 5413–5419.PubMedCrossRef

67.

Okada, M., Nada, S., Yamanashi, Y., Yamamoto, T., & Nakagawa, H. (1991). CSK: A protein-tyrosine kinase involved in regulation of src family kinases. Journal of Biological Chemistry, 266, 24249–24252.PubMed

68.

Kunte, D. P., Wali, R. K., Koetsier, J. L., Hart, J., Kostjukova, M. N., Kilimnik, A. Y., et al. (2005). Down-regulation of the tumor suppressor gene C-terminal Src kinase: an early event during premalignant colonic epithelial hyperproliferation. FEBS Letters, 579, 3497–3502.PubMedCrossRef

69.

Defilippi, P., Di Stefano, P., & Cabodi, S. (2006). p130Cas: A versatile scaffold in signaling networks. Trends in Cell Biology, 16, 257–263.PubMedCrossRef

70.

Achiwa, H., & Lazo, J. S. (2007). PRL-1 tyrosine phosphatase regulates c-Src levels, adherence, and invasion in human lung cancer cells. Cancer Research, 67, 643–650.PubMedCrossRef

71.

Shah, A. N., & Gallick, G. E. (2007). Src, chemoresistance and epithelial to mesenchymal transition: are they related? Anti-Cancer Drugs, 18, 371–375.PubMedCrossRef

72.

Cheng, J. Q., Lindsley, C. W., Cheng, G. Z., Yang, H., & Nicosia, S. V. (2005). The Akt/PKB pathway: molecular target for cancer drug discovery. Oncogene, 24, 7482–7492.PubMedCrossRef

73.

Avizienyte, E., & Frame, M. C. (2005). Src and FAK signalling controls adhesion fate and the epithelial-to-mesenchymal transition. Current Opinion in Cell Biology, 17, 542–547.PubMedCrossRef

74.

Werner, S. R., Lee, P. A., DeCamp, M. W., Crowell, D. N., Randall, S. K., & Crowell, P. L. (2003). Enhanced cell cycle progression and down regulation of p21(Cip1/Waf1) by PRL tyrosine phosphatases. Cancer Letters, 202, 201–211.PubMedCrossRef

75.

Gnainsky, Y., Spira, G., Paizi, M., Bruck, R., Nagler, A., Genina, O., et al. (2006). Involvement of the tyrosine phosphatase early gene of liver regeneration (PRL-1) in cell cycle and in liver regeneration and fibrosis effect of halofuginone. Cell and Tissue Research, 324, 385–394.PubMedCrossRef

76.

Kadambi, V. J., Lorenz, J. N., Stagliano, N. E., Matter, W. F., Wang, X. S., Bloem, L., et al. (2000). Impaired ventricular relaxation resulting from cardiac-specific overexpression of a human prenylated protein tyrosine phosphatase. Circulation (Suppl), 102, II–268.

77.

Chinnaiyan, K. M., Alexander, D., & McCullough, P. A. (2005). Role of angiotensin II in the evolution of diastolic heart failure. Journal of Clinical Hypertension (Greenwich), 7, 740–747.CrossRef

78.

Ehrlich, J. R., Hohnloser, S. H., & Nattel, S. (2006). Role of angiotensin system and effects of its inhibition in atrial fibrillation: Clinical and experimental evidence. European Heart Journal, 27, 512–518.PubMedCrossRef

79.

Peters, C. S., Liang, X., Li, S., Kannan, S., Peng, Y., Taub, R., et al. (2001). ATF-7, a novel bZIP protein, interacts with the PRL-1 protein-tyrosine phosphatase. Journal of Biological Chemistry, 276, 13718–13726.PubMedCrossRef

80.

Monaco, S. E., Angelastro, J. M., Szabolcs, M., & Greene, L. A. (2007). The transcription factor ATF5 is widely expressed in carcinomas, and interference with its function selectively kills neoplastic, but not nontransformed, breast cell lines. International Journal of Cancer, 120, 1883–1890.CrossRef

81.

Zerial, M., & McBride, H. (2001). Rab proteins as membrane organizers. Nature Reviews Molecular Cell Biology, 2, 107–117.PubMedCrossRef

82.

Magnusson, C., Svensson, A., Christerson, U., & Tagerud, S. (2005). Denervation-induced alterations in gene expression in mouse skeletal muscle. European Journal of Neuroscience, 21, 577–580.PubMedCrossRef

83.

Yuan, L., Chen, J., Lin, B., Zhang, J., & Zhang, S. (2007). Differential expression and functional constraint of PRL-2 in hibernating bat. Comparative Biochemistry and Physiology. Part B, Biochemistry and Molecular Biology, 148, 375–381.CrossRef

84.

Peng, Y., Du, K., Ramirez, S., Diamond, R. H., & Taub, R. (1999). Mitogenic up-regulation of the PRL-1 protein-tyrosine phosphatase gene by Egr-1. Egr-1 activation is an early event in liver regeneration. Journal of Biological Chemistry, 274, 4513–4520.PubMedCrossRef

85.

Peng, Y., Genin, A., Spinner, N. B., Diamond, R. H., & Taub, R. (1998). The gene encoding human nuclear protein tyrosine phosphatase, PRL-1. Cloning, chromosomal localization, and identification of an intron enhancer. Journal of Biological Chemistry, 273, 17286–17295.PubMedCrossRef

86.

Gregory, R. C., Lord, K. A., Panek, L. B., Gaines, P., Dillon, S. B., & Wojchowski, D. M. (2000). Subtraction cloning and initial characterization of novel epo-immediate response genes. Cytokine, 12, 845–857.PubMedCrossRef

87.

McLean, D. J., Friel, P. J., Pouchnik, D., & Griswold, M. D. (2002). Oligonucleotide microarray analysis of gene expression in follicle-stimulating hormone-treated rat Sertoli cells. Molecular Endocrinology, 16, 2780–2792.PubMedCrossRef

88.

Schmidt, J., de Avila, J., & McLean, D. (2006). Regulation of protein tyrosine phosphatase 4a1, B-cell translocation gene 2, nuclear receptor subfamily 4a1 and diacylglycerol O-acyltransferase 1 by follicle stimulating hormone in the rat ovary. Reproduction, Fertility, and Development, 18, 757–765.PubMedCrossRef

89.

Scarlato, M., Beesley, J., & Pleasure, D. (2000). Analysis of oligodendroglial differentiation using cDNA arrays. Journal of Neuroscience Research, 59, 430–435.PubMedCrossRef

90.

Takano, S., Fukuyama, H., Fukumoto, M., Kimura, J., Xue, J. H., Ohashi, H., et al. (1996). PRL-1, a protein tyrosine phosphatase, is expressed in neurons and oligodendrocytes in the brain and induced in the cerebral cortex following transient forebrain ischemia. Brain Research. Molecular Brain Research, 40, 105–115.PubMedCrossRef

91.

Grimes, J. A., Fraser, S. P., Stephens, G. J., Downing, J. E., Laniado, M. E., Foster, C. S., et al. (1995). Differential expression of voltage-activated Na+ currents in two prostatic tumour cell lines: Contribution to invasiveness in vitro. FEBS Letters, 369, 290–294.PubMedCrossRef

92.

Fraser, S. P., Salvador, V., Manning, E. A., Mizal, J., Altun, S., Raza, M., et al. (2003). Contribution of functional voltage-gated Na+ channel expression to cell behaviors involved in the metastatic cascade in rat prostate cancer: I. Lateral motility. Journal of Cellular Physiology, 195, 479–487.PubMedCrossRef

93.

Raghavendra Prasad, H. S., Qi, Z., Srinivasan, K. N., & Gopalakrishnakone, P. (2004). Potential effects of tetrodotoxin exposure to human glial cells postulated using microarray approach. Toxicon, 44, 597–608.PubMedCrossRef

94.

Tonks, N. K. (2005). Redox redux: Revisiting PTPs and the control of cell signaling. Cell, 121, 667–670.PubMedCrossRef

95.

den Hertog, J., Groen, A., & van der Wijk, T. (2005). Redox regulation of protein-tyrosine phosphatases. Archives of Biochemistry and Biophysics, 434, 11–15.PubMedCrossRef

96.

Ahn, J. H., Kim, S. J., Park, W. S., Cho, S. Y., Ha, J. D., Kim, S. S., et al. (2006). Synthesis and biological evaluation of rhodanine derivatives as PRL-3 inhibitors. Bioorganic and Medicinal Chemistry Letters, 16, 2996–2999.PubMedCrossRef

97.

Choi, S. K., Oh, H. M., Lee, S. K., Jeong, D. G., Ryu, S. E., Son, K. H., et al. (2006). Biflavonoids inhibited phosphatase of regenerating liver-3 (PRL-3). Natural Product Research, 20, 341–346.PubMedCrossRef

98.

Dursina, B., Reents, R., Delon, C., Wu, Y., Kulharia, M., Thutewohl, M., et al. (2006). Identification and specificity profiling of protein prenyltransferase inhibitors using new fluorescent phosphoisoprenoids. Journal of the American Chemical Society, 128, 2822–2835.PubMedCrossRef

99.

Pathak, M. K., Dhawan, D., Lindner, D. J., Borden, E. C., Farver, C., & Yi, T. (2002). Pentamidine is an inhibitor of PRL phosphatases with anticancer activity. Molecular Cancer Therapeutics, 1, 1255–1264.PubMed

100.

Sands, M., Kron, M. A., & Brown, R. B. (1985). Pentamidine: A review. Reviews of Infectious Diseases, 7, 625–634.PubMed

101.

Wani, M. C., Taylor, H. L., Wall, M. E., Coggon, P., & McPhail, A. T. (1971). Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. Journal of the American Chemical Society, 93, 2325–2327.PubMedCrossRef

102.

Lebowitz, P. F., Casey, P. J., Prendergast, G. C., & Thissen, J. A. (1997). Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB. Journal of Biological Chemistry, 272, 15591–15594.PubMedCrossRef

103.

Whyte, D. B., Kirschmeier, P., Hockenberry, T. N., Nunez-Oliva, I., James, L., Catino, J. J., et al. (1997). K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. Journal of Biological Chemistry, 272, 14459–14464.PubMedCrossRef

104.

Rowell, C. A., Kowalczyk, J. J., Lewis, M. D., & Garcia, A. M. (1997). Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo. Journal of Biological Chemistry, 272, 14093–14097.PubMedCrossRef

105.

Mijimolle, N., Velasco, J., Dubus, P., Guerra, C., Weinbaum, C. A., Casey, P. J., et al. (2005). Protein farnesyltransferase in embryogenesis, adult homeostasis, and tumor development. Cancer Cell, 7, 313–324.PubMedCrossRef

106.

Konstantinopoulos, P. A., Karamouzis, M. V., & Papavassiliou, A. G. (2007). Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Nature Reviews Drug Discovery, 6, 541–555.PubMedCrossRef

107.

Parker, B. S., Argani, P., Cook, B. P., Liangfeng, H., Chartrand, S. D., Zhang, M., et al. (2004). Alterations in vascular gene expression in invasive breast carcinoma. Cancer Research, 64, 7857–7866.PubMedCrossRef

108.

Anant, J. S., Desnoyers, L., Machius, M., Demeler, B., Hansen, J. C., Westover, K. D., et al. (1998). Mechanism of Rab geranylgeranylation: formation of the catalytic ternary complex. Biochemistry, 37, 12559–12568.PubMedCrossRef

109.

Andres, D. A., Seabra, M. C., Brown, M. S., Armstrong, S. A., Smeland, T. E., Cremers, F. P., et al. (1993). cDNA cloning of component A of Rab geranylgeranyl transferase and demonstration of its role as a Rab escort protein. Cell, 73, 1091–1099.PubMedCrossRef

Titel: PRL PTPs: mediators and markers of cancer progression
verfasst von: Darrell C. Bessette
Dexin Qiu
Catherine J. Pallen
Publikationsdatum: 01.06.2008
Verlag: Springer US
Erschienen in: Cancer and Metastasis Reviews / Ausgabe 2/2008
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-008-9121-3

Springer Medizin

PRL PTPs: mediators and markers of cancer progression

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2008

Dual-specificity MAP kinase phosphatases (MKPs) and cancer

Targeting PTPs with small molecule inhibitors in cancer treatment

Targeted therapy for oesophageal cancer: an overview

Preface

Biography - Stephen M. Keyse

The tyrosine phosphatase Shp2 (PTPN11) in cancer

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie